Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Embrace Watch Usability in Dravet Syndrome
NCT03299842Phase 3Terminated
- Sponsor
- Zogenix, Inc.
- Start
- Jul 2017
- Primary completion
- Jul 2018
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in Dravet syndrome, sponsored by Zogenix, Inc. Primary endpoint: Overall Usability of the Empatica Embrace Seizure Detection Watch System at 12 weeks. Started Jul 2017; status: terminated.
02
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT03299842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299842.